Showing results (2411-2420 of 2,541) with videos related to
Sort By:
Pageof 255
Blood Advances|December 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphomaSasanka M Handunnetti, Amit Khot, Piers Blombery, et al.Cell Discovery|June 4, 2024
Specialized Tfh cell subsets driving type-1 and type-2 humoral responses in lymphoid tissueSaumya Kumar, Afonso P Basto, Filipa Ribeiro, et al.Cell Death and Differentiation|January 29, 2020
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cellsCharis E Teh, Jia-Nan Gong, David Segal, et al.Leukemia|April 9, 2016
BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cellsZ Xu, P P Sharp, Y Yao, et al.Blood|April 24, 2009
Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant functionSimone M Schoenwaelder, Yuping Yuan, Emma C Josefsson, et al.Blood|April 27, 2019
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variablesAndrew W Roberts, Shuo Ma, Thomas J Kipps, et al.Cell Death & Disease|October 13, 2012
Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributorL M Lindqvist, I Vikström, J M Chambers, et al.Chemmedchem|June 19, 2013
Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondiiJozef Stec, Alina Fomovska, Gustavo A Afanador, et al.Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.Proceedings of the National Academy of Sciences of the United States of America|September 9, 2010
Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in miceWilliam S Stevenson, Craig D Hyland, Jian-Guo Zhang, et al.Pageof 255